Arrowhead Pharmaceuticals, Inc.

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 13/09/2024 BST			5-day change	1st Jan Change
21.49 ^USD	+6.20%		-3.29%	-29.77%

09-10	Arrowhead Pharmaceuticals' Plozasiran Receives FDA Breakthrough Therapy Designation	MT
09-10	Arrowhead Pharmaceuticals Gets FDA Breakthrough Designation for Plozasiran	DJ

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals' Plozasiran Receives FDA Breakthrough Therapy Designation	09-10	MT
Arrowhead Pharmaceuticals Gets FDA Breakthrough Designation for Plozasiran	09-10	DJ
Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday	09-03	MT
Transcript : Arrowhead Pharmaceuticals, Inc. - Shareholder/Analyst Call	09-03
Arrowhead Pharmaceuticals Shares Climb on Plans to File New Drug Application for Plozasiran	09-03	DJ
Arrowhead Pharmaceuticals Says Phase 3 Study of Plozasiran Met Primary Endpoint	09-03	MT
Arrowhead Pharmaceuticals, Inc. Presents New Pivotal Phase 3 Data At ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome	09-02	CI
Investors already know...	08-22
Analyst recommendations: Estee Lauder, Sentinelone, Snowflake, Wolfspeed, Admiral...	08-22
Arrowhead Pharmaceuticals to Advance Two Drug Candidates in Clinical Trials on Obesity	08-14	MT
Arrowhead Pharmaceuticals to Advance Two Treatments for Obesity, Metabolic Diseases	08-14	DJ
Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call	08-14
Arrowhead Pharmaceuticals, Inc. to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, into Clinical Studies	08-14	CI
Tech, Yen, and Jobs: Wall Street's triple play	08-09
Analyst recommendations: Epam Systems, Five9, T-Mobile, Lyft, Under Armour...	08-09
Arrowhead Pharmaceuticals Fiscal Q3 Loss Widens; Secures $500 Million Credit Facility From Sixth Street	08-08	MT
Transcript : Arrowhead Pharmaceuticals, Inc., Q3 2024 Earnings Call, Aug 08, 2024	08-08
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2024	08-08	CI
Arrowhead Pharmaceuticals, Inc. Announces $500 Million Strategic Financing Facility with Sixth Street	08-08	CI
Tech's Judgment Day	07-23
Analyst recommendations: CrowdStrike, Johnson & Johnson, Netflix, Nvidia, Snap...	07-23
Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call	07-16
HC Wainwright Cuts Price Target on Arrowhead Pharmaceuticals to $60 From $90, Keeps Buy Rating	07-05	MT
Arrowhead Pharmaceuticals to Advance Investigational Medicine Plozasiran Into Late-stage Cardiovascular Study	06-25	MT
Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call	06-25

Chart Arrowhead Pharmaceuticals, Inc.

Duration

Period

More charts

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Employees

525

Sector

Biotechnology & Medical Research

Calendar

24/09/2024 - R&D Webinar - Central Nervous System

More about the company